Quince Therapeutics Q2 net loss widens on acquisition charges
QNCX•Outlook
- Quince expects Phase 2 data for LAM-001 in BOS in Q1 2027
- Phase 2b data for LAM-001 in PH-ILD anticipated in Q1 2028
- Company expects cash position to fund operations through end of 2028
Overview
- US biopharmaceutical developer completed Orphai acquisition, adding LAM-001 to late-stage pulmonary pipeline
- Company closed $115 mln private placement financing, boosting cash to $116 mln as of June 30, 2026
- Q2 net loss widened due to acquisition-related charges and increased G&A expenses
Result Drivers
- Acquisition-related charges - Net loss increased due to one-time charges from the Orphai acquisition and assumption of historical options
- Pipeline expansion - Acquisition of Orphai added LAM-001, advancing late-stage pulmonary disease programs
- R&D spending shift - Overall R&D expense fell as eDSP program wound down, while LAM-001 costs increased due to study start-up
Analyst Coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
Related News
VolitionRx posts corporate deck outlining licensing-led strategy for Nu.Q diagnostics in cancer, sepsis, veterinary testing
VNRX•
MicroVision prices USD 17 million public offering at USD 2.5 per unit
MVIS•
